Payment overview · 2025
General Payments
$860.46
45 reported records · 15 companies
Healthcare provider profile · identity verified
Cheryl Hranicky, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ROSTRAVER TOWNSHIP, PA · NPI 1629086574
Verified facts
What the public records show
CMS Open Payments records show Cheryl Hranicky, CRNP received $860.46 in general payments during 2025 across 45 reported records.
Novo Nordisk Inc accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Ozempic, Rybelsus, Trelegy Ellipta.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $293.30 | 34.1% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.78 | 11.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.91 | 7.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.23 | 6.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.74 | 4.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.60 | 4.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.68 | 4.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.01 | 4.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.97 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.93 | 4.1% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.11 | 4.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.30 | 3.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.49 | 3.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.72 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.69 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $860.46 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $144.08 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.22 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.22 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.23 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.88 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $47.91 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.90 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.90 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.90 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.74 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.68 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $36.01 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.47 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $29.47 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.49 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 15 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 261 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
261 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
261 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 550 | 159 |
| Pantoprazole Sodium | Pantoprazole Sodium | 458 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 384 | 105 |
| Eliquis | Apixaban | 261 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 74 |
| Metformin Hcl | Metformin Hcl | 241 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 203 | 55 |
| Gabapentin | Gabapentin | 202 | 47 |
| Simvastatin | Simvastatin | 196 | 45 |
| Lisinopril | Lisinopril | 190 | 56 |
| Irbesartan | Irbesartan | 165 | 41 |
| Sertraline Hcl | Sertraline Hcl | 158 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 59 |
| Furosemide | Furosemide | 151 | 52 |
| Omeprazole | Omeprazole | 132 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 36 |
| Jardiance | Empagliflozin | 124 | 25 |
| Losartan Potassium | Losartan Potassium | 121 | 38 |
| Ozempic | Semaglutide | 121 | 23 |
| Allopurinol | Allopurinol | 118 | 33 |
| Synthroid | Levothyroxine Sodium | 114 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 32 |
| Alendronate Sodium | Alendronate Sodium | 107 | 30 |
| Famotidine | Famotidine | 107 | 40 |
| Potassium Chloride | Potassium Chloride | 106 | 32 |
| Donepezil Hcl | Donepezil Hcl | 98 | 23 |
| Valsartan | Valsartan | 98 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 24 |
| Meloxicam | Meloxicam | 95 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 41 |
| Glimepiride | Glimepiride | 92 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 26 |
| Alprazolam | Alprazolam | 85 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 85 | 20 |
| Memantine Hcl | Memantine Hcl | 77 | 13 |
| Montelukast Sodium | Montelukast Sodium | 74 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 72 | 21 |
| Mirtazapine | Mirtazapine | 70 | 19 |
| Lorazepam | Lorazepam | 66 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 17 |
| Trazodone Hcl | Trazodone Hcl | 63 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 62 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 16 |
| Benazepril Hcl | Benazepril Hcl | 57 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 55 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 18 |
| Prednisone | Prednisone | 53 | 43 |
| Atenolol | Atenolol | 52 | 14 |
| Repatha Sureclick | Evolocumab | 52 | suppressed |
| Clonazepam | Clonazepam | 51 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 11 |
| Metformin Hcl Er | Metformin Hcl | 47 | 12 |
| Carvedilol | Carvedilol | 43 | 16 |
| Methylprednisolone | Methylprednisolone | 41 | 36 |
| Spironolactone | Spironolactone | 40 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Glipizide Er | Glipizide | 37 | 14 |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 20 |
| Meclizine Hcl | Meclizine Hcl | 35 | 20 |
| Rybelsus | Semaglutide | 34 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 33 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 15 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Cephalexin | Cephalexin | 21 | suppressed |
| Repaglinide | Repaglinide | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $860.46 · 45 records | Novo Nordisk Inc | ABRYSVO, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, KEVEYIS, KISUNLA, Kerendia, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error